Other Clients/Companies To Watch:
Access Pharmaceuticals,
Inc
(OTC: ACCP)
Alexza
Pharmaceuticals, Inc.
(NASDAQ:ALXA)
Crucell
N.V.
(Euronext, NASDAQ: CRXL)
DelSite
Biotechnologies, Inc.
(OTC: DSII)
Digital
Angel Corporation
(AMEX:DOC)
Duska Therapeutics,
Inc.
(OTC:DSKA)
KERYX Biopharmaceuticals,
Inc.
(NASDAQ:KERX)
Manhattan Pharmaceuticals,
Inc.
(AMEX:MHA)
Mediware Information Systems, Inc. (NASDAQ: MEDW)
Pipex Pharmaceuticals,
Inc.
(OTC:PPXP.OB)
Redpoint Bio Corporation
(OTC:RPBC)
Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Duska is developing a portfolio of investigational medicines, two of which are in late stages of clinical testing. Duska's ATPace(TM) is expected to enter a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia. Duska's CDP-1050 is expected to commence a Phase 2 clinical trial for the treatment of heart failure. In addition, Duska has a preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For more information, visit http://www.duskatherapeutics.com.